Evaluation of a breast cancer nomogram for predicting risk of ipsilateral breast tumor recurrences in patients with ductal carcinoma in situ after local excision
- PMID: 22253459
- PMCID: PMC3295558
- DOI: 10.1200/JCO.2011.36.4976
Evaluation of a breast cancer nomogram for predicting risk of ipsilateral breast tumor recurrences in patients with ductal carcinoma in situ after local excision
Erratum in
- J Clin Oncol. 2012 Jul 1;30(19):2424
Abstract
Purpose: Prediction of patients at highest risk for ipsilateral breast tumor recurrence (IBTR) after local excision of ductal carcinoma in situ (DCIS) remains a clinical concern. The aim of our study was to evaluate a published nomogram from Memorial Sloan-Kettering Cancer Center to predict for risk of IBTR in patients with DCIS from our institution.
Patients and methods: We retrospectively identified 794 patients with a diagnosis of DCIS who had undergone local excision from 1990 through 2007 at the MD Anderson Cancer Center (MDACC). Clinicopathologic factors and the performance of the Memorial Sloan-Kettering Cancer Center nomogram for prediction of IBTR were assessed for 734 patients who had complete data.
Results: There was a marked difference with respect to tumor grade, prevalence of necrosis, initial presentation, final margins, and receipt of endocrine therapy between the two cohorts. The biggest difference was that more patients received radiation in the MDACC cohort (75% at MDACC v 49% at MSKCC; P < .001). Follow-up time in the MDACC cohort was longer than in the MSKCC cohort (median 7.1 years v 5.6 years), and the recurrence rate was lower in the MDACC cohort (7.9% v 11%). The median 5-year probability of recurrence was 5%, and the median 10-year probability of recurrence was 7%. The nomogram for prediction of 5- and 10-year IBTR probabilities demonstrated imperfect calibration and discrimination, with a concordance index of 0.63.
Conclusion: Predictive models for IBTR in patients with DCIS who were treated with local excision are imperfect. Our current ability to accurately predict recurrence on the basis of clinical parameters alone is limited.
Conflict of interest statement
Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.
Figures


Comment in
-
Selecting individualized treatment for patients with ductal carcinoma in situ of the breast: the search continues.J Clin Oncol. 2012 Feb 20;30(6):577-9. doi: 10.1200/JCO.2011.39.6929. Epub 2012 Jan 17. J Clin Oncol. 2012. PMID: 22253465 No abstract available.
-
Validation of a nomogram for predicting risk of local recurrence for ductal carcinoma in situ.J Clin Oncol. 2012 Sep 1;30(25):3143-4; author reply 3144-5. doi: 10.1200/JCO.2012.43.9067. Epub 2012 Jul 23. J Clin Oncol. 2012. PMID: 22826276 No abstract available.
Similar articles
-
Validation of a nomogram in the prediction of local recurrence risks after conserving surgery for Asian women with ductal carcinoma in situ of the breast.Clin Oncol (R Coll Radiol). 2014 Nov;26(11):684-91. doi: 10.1016/j.clon.2014.08.004. Epub 2014 Sep 4. Clin Oncol (R Coll Radiol). 2014. PMID: 25194727
-
A Nomogram Using Imaging Features to Predict Ipsilateral Breast Tumor Recurrence After Breast-Conserving Surgery for Ductal Carcinoma In Situ.Korean J Radiol. 2024 Oct;25(10):876-886. doi: 10.3348/kjr.2024.0268. Korean J Radiol. 2024. PMID: 39344545 Free PMC article.
-
Local relapse after breast-conserving therapy for ductal carcinoma in situ: a European single-center experience and external validation of the Memorial Sloan-Kettering Cancer Center DCIS nomogram.Cancer J. 2014 Jan-Feb;20(1):1-7. doi: 10.1097/PPO.0000000000000025. Cancer J. 2014. PMID: 24445756
-
Society of Surgical Oncology-American Society for Radiation Oncology-American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Ductal Carcinoma In Situ.J Clin Oncol. 2016 Nov 20;34(33):4040-4046. doi: 10.1200/JCO.2016.68.3573. Epub 2016 Oct 31. J Clin Oncol. 2016. PMID: 27528719 Free PMC article.
-
Patterns of invasive recurrence among patients originally treated for ductal carcinoma in situ by breast-conserving surgery versus mastectomy.Breast Cancer Res Treat. 2021 Apr;186(3):617-624. doi: 10.1007/s10549-021-06129-3. Epub 2021 Mar 6. Breast Cancer Res Treat. 2021. PMID: 33675490 Free PMC article. Review.
Cited by
-
Development and validation of a prediction model of poor performance status and severe symptoms over time in cancer patients (PROVIEW+).Palliat Med. 2021 Oct;35(9):1713-1723. doi: 10.1177/02692163211019302. Epub 2021 Jun 15. Palliat Med. 2021. PMID: 34128429 Free PMC article.
-
Epidemiology, Biology, Treatment, and Prevention of Ductal Carcinoma In Situ (DCIS).JNCI Cancer Spectr. 2018 Nov;2(4):pky063. doi: 10.1093/jncics/pky063. Epub 2018 Dec 27. JNCI Cancer Spectr. 2018. PMID: 30627695 Free PMC article.
-
Tools to Guide Radiation Oncologists in the Management of DCIS.Healthcare (Basel). 2024 Apr 6;12(7):795. doi: 10.3390/healthcare12070795. Healthcare (Basel). 2024. PMID: 38610216 Free PMC article. Review.
-
How Can Advanced Imaging Be Used to Mitigate Potential Breast Cancer Overdiagnosis?Acad Radiol. 2016 Jun;23(6):768-73. doi: 10.1016/j.acra.2016.02.008. Epub 2016 Mar 23. Acad Radiol. 2016. PMID: 27017136 Free PMC article. Review.
-
Comparative effectiveness of incorporating a hypothetical DCIS prognostic marker into breast cancer screening.Breast Cancer Res Treat. 2018 Feb;168(1):229-239. doi: 10.1007/s10549-017-4582-0. Epub 2017 Nov 28. Breast Cancer Res Treat. 2018. PMID: 29185118 Free PMC article.
References
-
- Baxter NN, Virnig BA, Durham SB, et al. Trends in the treatment of ductal carcinoma in situ of the breast. J Natl Cancer Inst. 2004;96:443–448. - PubMed
-
- Allegra CJ, Aberle DR, Ganschow P, et al. National Institutes of Health State-of-the-Science Conference statement: Diagnosis and management of ductal carcinoma in situ September 22-24, 2009. J Natl Cancer Inst. 2010;102:161–169. - PubMed
-
- Fisher B, Land S, Mamounas E, et al. Prevention of invasive breast cancer in women with ductal carcinoma in situ: An update of the National Surgical Adjuvant Breast and Bowel Project experience. Semin Oncol. 2001;28:400–418. - PubMed
-
- Ceilley E, Jagsi R, Goldberg S, et al. The management of ductal carcinoma in situ in North America and Europe: Results of a survey. Cancer. 2004;101:1958–1967. - PubMed
-
- Bijker N, Meijnen P, Peterse JL, et al. Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: Ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853—A study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol. 2006;24:3381–3387. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical